胸腺肽α1预防慢性阻塞性肺疾病稳定期急性加重的有效性及安全性Meta分析OACSTPCD

Objective To systematically assess the efficacy and safety of thymosin α1 in preventing acute exacerbation in patients with stable phase of chronic obstructive pulmonary disease(SPCOPD).Methods The randomized controlled trails(RCT)related to the efficacy of thymosin α1 in the treatment of patients with SPCOPD in the PubMed,Embase,Medline,The Cochrane Library,CBM,WanFang,CNKI and VIP databases were searched from their inception to December 2022.The Cochrane Risk Bias Assessment Tool 2.0 was used to assess the basis risk of the literature was evaluated.Meta-analysis was conducted by the RevMan 5.3 software.Results Ten RCTs involving 811 patients were included.In terms of efficacy,the Meta-analysis results showed that thymosin α1 reduced the number of acute exacerbations in SPCOPD patients[MD=-0.96,95% CI(-1.59,-0.32),P=0.003]and the days of acute exacerbation[MD=-9.14,95% CI(-11.71,-6.56),P<0.000 01],improved forced expiratory volume in the first second(FEV1)[MD=0.12,95% CI(0.00,0.24),P=0.04],and regulated T lymphocyte subsets CD4[MD=6.66,95% CI(4.39,8.93),P<0.000 01],T lymphocyte subsets CD8[MD=-6.00,95% CI(-8.96,-3.04),P<0.000 01],and CD4/CD8[MD=0.61,95% CI(0.39,0.84),P<0.000 01].In terms of safety,the Meta-analysis results showed that only a few patients had mild adverse reactions such as nausea,dry mouth,and pharyngeal discomfort,which could be self-relieved.Conclusion Thymosin α1 has good efficacy and safety in preventing acute exacerbation of SPCOPD.